

SAFETY DATA SHEET

Section 1. Identification			
Product identifier	: 718A		
Product name	: Centari Monastral Maroon		
Other means of identification	: 1250004162		
Date of issue	: 1/18/2024		
Version	: 15.01		
Relevant identified uses of the substance or mixture and uses advised against			
Identified uses	: Coating component.		
Uses advised against	: Not for sale to or use by consumers.		
Supplier's details	: Axalta Coating Systems, LLC 50 Applied Bank Blvd. Suite 300 Glen Mills, PA 19342 USA		
Product information	855-6AXALTA		
Emergency telephone number	: (CHEMTREC) - 800-424-9300		

Section 2. Hazards identification

OSHA/HCS status	: This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).
Classification of the substance or mixture	 FLAMMABLE LIQUIDS - Category 2 ACUTE TOXICITY (inhalation) - Category 4 SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2A SKIN SENSITIZATION - Category 1 CARCINOGENICITY - Category 2 TOXIC TO REPRODUCTION - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Narcotic effects) - Category 3 SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 2 Percentage of the mixture consisting of ingredient(s) of unknown acute toxicity: 15.5%
<u>GHS label elements</u> Hazard pictograms	

Signal word

: Danger

Section 2. Hazards identification

Hazard statements	 H225 - Highly flammable liquid and vapor. H315 - Causes skin irritation. H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation. H332 - Harmful if inhaled. H335 - May cause respiratory irritation. H336 - May cause drowsiness or dizziness. H351 - Suspected of causing cancer. H361 - Suspected of damaging fertility or the unborn child. H373 - May cause damage to organs through prolonged or repeated exposure.
Precautionary statements	
Prevention	 P201 - Obtain special instructions before use. P280 - Wear protective gloves, protective clothing and eye or face protection. P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P241 - Use explosion-proof electrical, ventilating or lighting equipment. P242 - Use non-sparking tools. P243 - Take action to prevent static discharges. P260 - Do not breathe vapor. P264 - Wash hands thoroughly after handling.
Response	 P308 + P313 - IF exposed or concerned: Get medical advice or attention. P304 + P312 - IF INHALED: Call a POISON CENTER or doctor if you feel unwell. P362 + P364 - Take off contaminated clothing and wash it before reuse. P363 - Wash contaminated clothing before reuse. P302 + P352 - IF ON SKIN: Wash with plenty of water. P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 - If eye irritation persists: Get medical advice or attention.
Storage	 P403 + P233 - Store in a well-ventilated place. Keep container tightly closed. P403 + P235 - Keep cool.
Disposal	 P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazards not otherwise classified	: None known.

Section 3. Composition/information on ingredients

Substance/mixture : Mixture		
Ingredient name	CAS number	Concentration
XYLENE	1330-20-7	≥10 - ≤25
Naphtha (petroleum), hydrotreated light	64742-49-0	≥10 - ≤25
TOLUENE	108-88-3	≤10
ETHYLBENZENE	100-41-4	≤10
BUTYL ACETATE	123-86-4	≤5
METHYL ETHYL KETONE	78-93-3	≤3
AROMATIC HYDROCARBON	64742-94-5	≤3
Tung oil	8001-20-5	<1

Section 3. Composition/information on ingredients

METHYL METHACRYLATE	80-62-6	≤0.3
NAPHTHALENE	91-20-3	≤0.3

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

Description of necessary first aid measures

 Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

Potential acute health effects	
Eye contact	: Causes serious eye irritation.
Inhalation	: Harmful if inhaled. Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. May cause respiratory irritation.
Skin contact	: Causes skin irritation. May cause an allergic skin reaction.
Ingestion	: Can cause central nervous system (CNS) depression.
Over-exposure signs/sympto	oms

Section 4. First aid measures

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: respiratory tract irritation coughing nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations
Skin contact	: Adverse symptoms may include the following: irritation redness reduced fetal weight increase in fetal deaths skeletal malformations
Ingestion	: Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations
Indication of immediate me	dical attention and special treatment needed, if necessary
Notes to physician	 In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Specific treatments	: No specific treatment.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water

before removing it, or wear gloves.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
Specific hazards arising from the chemical	: Highly flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.
Hazardous thermal decomposition products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides

Section 5. Fire-fighting measures

Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
Environmental precautions	:	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

Section 7. Handling and storage

Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapor or mist. Do not ingest. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof
	electrical (ventilating, lighting and material handling) equipment. Use only non-sparking

Section 7. Handling and storage

	tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
Conditions for safe storage, including any incompatibilities	: Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.
Storage code	: IA

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
XYLENE	OSHA PEL 1989 (United States, 3/1989). [Xylenes (o-, m-, p-isomers)] TWA: 100 ppm 8 hours. TWA: 435 mg/m ³ 8 hours. STEL: 150 ppm 15 minutes. STEL: 655 mg/m ³ 15 minutes. OSHA PEL (United States, 5/2018). [Xylenes (o-, m-, p- isomers)] TWA: 100 ppm 8 hours. TWA: 435 mg/m ³ 8 hours. CAL OSHA PEL (United States, 5/2018). [xylene] STEL: 655 mg/m ³ 15 minutes. STEL: 150 ppm 15 minutes. C: 300 ppm TWA: 435 mg/m ³ 8 hours. TWA: 100 ppm 8 hours. ACGIH TLV (United States, 1/2022). [p-xylene and mixtures containing p-xylene] Ototoxicant. TWA: 20 ppm 8 hours.
Naphtha (petroleum), hydrotreated light	None.
TOLUENE	OSHA PEL 1989 (United States, 3/1989). TWA: 100 ppm 8 hours. TWA: 375 mg/m ³ 8 hours. STEL: 150 ppm 15 minutes. STEL: 560 mg/m ³ 15 minutes. OSHA PEL Z2 (United States, 2/2013). TWA: 200 ppm 8 hours. CEIL: 300 ppm

Section 8. Exposure controls/personal protection AMP: 500 ppm 10 minutes. NIOSH REL (United States, 10/2020). TWA: 100 ppm 10 hours. TWA: 375 mg/m³ 10 hours. STEL: 150 ppm 15 minutes. STEL: 560 mg/m³ 15 minutes. ACGIH TLV (United States, 1/2022). Ototoxicant. TWA: 20 ppm 8 hours. CAL OSHA PEL (United States, 5/2018). Absorbed through skin. STEL: 560 mg/m³ 15 minutes. STEL: 150 ppm 15 minutes. C: 500 ppm TWA: 37 mg/m³ 8 hours. TWA: 10 ppm 8 hours. ACGIH TLV (United States, 1/2022). Ototoxicant. **ETHYLBENZENE** TWA: 20 ppm 8 hours. OSHA PEL 1989 (United States, 3/1989). TWA: 100 ppm 8 hours. TWA: 435 mg/m³ 8 hours. STEL: 125 ppm 15 minutes. STEL: 545 mg/m³ 15 minutes. NIOSH REL (United States, 10/2020). TWA: 100 ppm 10 hours. TWA: 435 mg/m³ 10 hours. STEL: 125 ppm 15 minutes. STEL: 545 mg/m³ 15 minutes. OSHA PEL (United States, 5/2018). TWA: 100 ppm 8 hours. TWA: 435 mg/m³ 8 hours. CAL OSHA PEL (United States, 5/2018). STEL: 130 mg/m³ 15 minutes. STEL: 30 ppm 15 minutes. TWA: 22 mg/m³ 8 hours. TWA: 5 ppm 8 hours. BUTYL ACETATE OSHA PEL 1989 (United States, 3/1989). TWA: 150 ppm 8 hours. TWA: 710 mg/m³ 8 hours. STEL: 200 ppm 15 minutes. STEL: 950 mg/m³ 15 minutes. NIOSH REL (United States, 10/2020). TWA: 150 ppm 10 hours. TWA: 710 mg/m³ 10 hours. STEL: 200 ppm 15 minutes. STEL: 950 mg/m³ 15 minutes. OSHA PEL (United States, 5/2018). TWA: 150 ppm 8 hours. TWA: 710 mg/m³ 8 hours. ACGIH TLV (United States, 1/2022). [Butyl acetates all isomers] STEL: 150 ppm 15 minutes. TWA: 50 ppm 8 hours. CAL OSHA PEL (United States, 5/2018). STEL: 950 mg/m³ 15 minutes.

Section 8. Exposure controls/personal protection

STEL: 200 ppm 15 minutes. TWA: 710 mg/m³ 8 hours. TWA: 150 ppm 8 hours. METHYL ETHYL KETONE ACGIH TLV (United States, 1/2022). TWA: 200 ppm 8 hours. TWA: 590 mg/m³ 8 hours. STEL: 300 ppm 15 minutes. STEL: 885 mg/m³ 15 minutes. OSHA PEL 1989 (United States, 3/1989). TWA: 200 ppm 8 hours. TWA: 590 mg/m³ 8 hours. STEL: 300 ppm 15 minutes. STEL: 885 mg/m³ 15 minutes. NIOSH REL (United States, 10/2020). TWA: 200 ppm 10 hours. TWA: 590 mg/m³ 10 hours. STEL: 300 ppm 15 minutes. STEL: 885 mg/m³ 15 minutes. OSHA PEL (United States, 5/2018). TWA: 200 ppm 8 hours. TWA: 590 mg/m³ 8 hours. CAL OSHA PEL (United States, 5/2018). STEL: 885 mg/m³ 15 minutes. STEL: 300 ppm 15 minutes. TWA: 590 mg/m³ 8 hours. TWA: 200 ppm 8 hours. AROMATIC HYDROCARBON None. Tung oil None. ACGIH TLV (United States, 1/2022). Skin sensitizer. METHYL METHACRYLATE TWA: 50 ppm 8 hours. STEL: 100 ppm 15 minutes. OSHA PEL 1989 (United States, 3/1989). TWA: 100 ppm 8 hours. TWA: 410 mg/m³ 8 hours. NIOSH REL (United States, 10/2020). TWA: 100 ppm 10 hours. TWA: 410 mg/m³ 10 hours. OSHA PEL (United States, 5/2018). TWA: 100 ppm 8 hours. TWA: 410 mg/m³ 8 hours. CAL OSHA PEL (United States, 5/2018). STEL: 410 mg/m³ 15 minutes. STEL: 100 ppm 15 minutes. TWA: 205 mg/m³ 8 hours. TWA: 50 ppm 8 hours. NAPHTHALENE ACGIH TLV (United States, 1/2022). Absorbed through skin. TWA: 10 ppm 8 hours. TWA: 52 mg/m³ 8 hours. OSHA PEL 1989 (United States, 3/1989).

Section 8. Exposure controls/personal protection

TWA: 10 ppm 8 hours.
TWA: 50 mg/m ³ 8 hours.
STEL: 15 ppm 15 minutes.
STEL: 75 mg/m ³ 15 minutes.
NIOSH REL (United States, 10/2020).
TWA: 10 ppm 10 hours.
TWA: 50 mg/m ³ 10 hours.
STEL: 15 ppm 15 minutes.
STEL: 75 mg/m ³ 15 minutes.
OSHA PEL (United States, 5/2018).
TWA: 10 ppm 8 hours.
TWA: 50 mg/m ³ 8 hours.
CAL OSHA PEL (United States, 5/2018). Absorbed
through skin.
TWA: 0.5 mg/m ³ 8 hours.
TWA: 0.1 ppm 8 hours.

Appropriate engineering controls	Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.
Environmental exposure controls	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.
Individual protection measure	
Hygiene measures	Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.
Skin protection	
Hand protection	Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
Body protection	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves.

Section 8. Exposure controls/personal protection

Other skin protection	 Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

Appearance	
Physical state	: Liquid.
Color	: Magenta.
Odor	: Not available.
Odor threshold	: Not available.
рН	: Not applicable.
Melting point	: Technically not possible to measure
Boiling point	: 108.9 to 148.9°C (228 to 300°F)
Flash point	: Closed cup: -7°C (19.4°F)
Evaporation rate	: Not available.
Flammability (solid, gas)	: Not available.
Lower and upper explosive (flammable) limits	: Lower: 0.9% Upper: 7%
Vapor pressure	: 1.3 kPa (9.6 mm Hg)
Vapor density	: Not available.
Density	: 0.946 g/cm ³
Partition coefficient: n- octanol/water	: Not applicable.
Auto-ignition temperature	: 220°C (428°F)
Decomposition temperature	: Not applicable.
Viscosity	: Not available.
Flow time (ISO 2431)	: Not available.

Section 10. Stability and reactivity

Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
Chemical stability	: The product is stable.
Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
Incompatible materials	: Reactive or incompatible with the following materials: oxidizing materials
Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure	
XYLENE	E LC50 Inhalation Gas. Rat		5000 ppm	4 hours	
	LD50 Oral	Rat	4300 mg/kg	-	
TOLUENE	LC50 Inhalation Vapor	Rat	49 g/m³	4 hours	
	LD50 Dermal	Rat	5001 mg/kg	-	
	LD50 Oral	Rat	5001 mg/kg	-	
	TDLo Dermal	Rat	26.4 mg/kg	-	
ETHYLBENZENE	LD50 Dermal	Rabbit	>5000 mg/kg	-	
	LD50 Oral	Rat	3500 mg/kg	-	
BUTYL ACETATE	LC50 Inhalation Vapor	Rat	21.1 mg/l	4 hours	
	LD50 Dermal	Rabbit	>17600 mg/kg	-	
	LD50 Oral	Rat	10768 mg/kg	-	
METHYL ETHYL KETONE	LD50 Dermal	Rabbit	6480 mg/kg	-	
	LD50 Oral	Rat	2737 mg/kg	-	
METHYL METHACRYLATE	LC50 Inhalation Vapor	Rat	78000 mg/m³	4 hours	
	LD50 Dermal	Rabbit	>5 g/kg	-	
	LD50 Oral	Rat	7872 mg/kg	-	
NAPHTHALENE	LD50 Dermal	Rabbit	>20 g/kg	-	
	LD50 Oral	Rat	490 mg/kg	-	

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation	
XYLENE	Eyes - Mild irritant	Rabbit	-	87 mg	-	
	Eyes - Severe irritant	Rabbit	-	24 hours 5	-	
				mg		
	Skin - Mild irritant	Rat	-	8 hours 60 uL	-	
	Skin - Moderate irritant	Rabbit	-	100 %	-	
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-	
				mg		
TOLUENE	Skin - Mild irritant	Pig	-	24 hours 250	-	
		_		uL		
	Skin - Mild irritant	Rabbit	-	435 mg	-	
ETHYLBENZENE	Skin - Mild irritant	Rabbit	-	24 hours 15	-	
				mg		
METHYL ETHYL KETONE	Skin - Mild irritant	Rabbit	-	24 hours 14	-	
				mg		
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-	
				mg		

Section 11. Toxicological information

	s 500		
HYDROCARBON uL			
NAPHTHALENESkin - Mild irritantRabbit-495 m		-	

Sensitization

Not available.

Mutagenicity

Not available.

Carcinogenicity

Not available.

Classification

Product/ingredient name	OSHA	IARC	NTP
XYLENE	-	3	-
TOLUENE	-	3	-
ETHYLBENZENE	-	2B	-
METHYL METHACRYLATE	-	3	-
NAPHTHALENE	-	2B	Reasonably anticipated to be a human carcinogen.

Reproductive toxicity

Not available.

Teratogenicity

Not available.

Specific target organ toxicity (single exposure)

Name	Category	Route of exposure	Target organs
XYLENE	Category 3	-	Respiratory tract irritation
Naphtha (petroleum), hydrotreated light	Category 3	-	Narcotic effects
TOLUENE	Category 3	-	Narcotic effects
BUTYL ACETATE	Category 3	-	Narcotic effects
METHYL ETHYL KETONE	Category 3	-	Narcotic effects
AROMATIC HYDROCARBON	Category 3	-	Narcotic effects
METHYL METHACRYLATE	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Name	Category	Route of exposure	Target organs
TOLUENE	Category 2	-	-
ETHYLBENZENE	Category 2	-	-
NAPHTHALENE	Category 2	-	blood

Aspiration hazard

Name	Result
XYLENE	ASPIRATION HAZARD - Category 1
Naphtha (petroleum), hydrotreated light	ASPIRATION HAZARD - Category 1
TOLUENË	ASPIRATION HAZARD - Category 1
ETHYLBENZENE	ASPIRATION HAZARD - Category 1
AROMATIC HYDROCARBON	ASPIRATION HAZARD - Category 1

Section 11. Toxicological information

Information on the likely : Not available. routes of exposure Potential acute health effects Eye contact : Causes serious eye irritation. Inhalation : Harmful If inhaled. Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. May cause respiratory irritation. Skin contact : Causes skin irritation. May cause an allergic skin reaction. Ingestion : Can cause central nervous system (CNS) depression. Symptoms related to the physical chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation oughing nause or voniting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Scienter exposure Potential immediate offects and also chronic effects from short and long term exposure Potential deathe effects Potential deadped effects : Not available. Potential cheads effects Potential cheads effects Potential immediate : Not available. Potential immediate : Not avai		
Eye contact : Causes serious eye irritation. Inhalation : Harmful if inhaled. Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. May cause respiratory irritation. Skin contact : Causes skin irritation. May cause an allergic skin reaction. Ingestion : Can cause central nervous system (CNS) depression. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain or inflation watering redness pain or inflation : Adverse symptoms may include the following: respiratory tract irritation coupling nausea or womiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations skeletal malformations skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malfo	Information on the likely routes of exposure	: Not available.
Inhalation : Harmful if inhaled. Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. May cause respiratory initation. Skin contact : Cau cause central nervous system (CNS) depression. Ingestion : Can cause central nervous system (CNS) depression. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing nauses or vomiting headache drowsines/faigue dizziness/strigue dizziness/strigue dizziness/strigue dizziness/strigue irritation reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Defentione infeatid deaths skeletal malformations <td< th=""><th>Potential acute health effects</th><th></th></td<>	Potential acute health effects	
drowsiness or dizziness. May cause respiratory irritation. Skin contact : Causes skin irritation. May cause an allergic skin reaction. Ingestion : Can cause central nervous system (CNS) depression. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing nausea or vomiting headache drowsiness/latigue dizziness/vertigo unconsciousness skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential inmediate : Not available. effects Potential delayed effects : Not available. effects Potential chronic health effects	Eye contact	: Causes serious eye irritation.
Ingestion : Can cause central nervous system (CNS) depression. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing nauses or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal mafformations Skin contact : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal mafformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal mafformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal mafformations Detential immediate effects and also chronic effects from short and long term exposure short term exposure Potential immediate offects Potential immediate offects : Not available. effects Potential immediate : Not available. effects	Inhalation	
Symptoms related to the physical, chemical and toxicological characteristics Eye contact Adverse symptoms may include the following: pain or initiation watering redness Inhalation Adverse symptoms may include the following: respiratory tract irritation coughing nausea or vomiting headache drowsiness/ratigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact Adverse symptoms may include the following: irritation reduced fetal weight increases in fetal deaths skeletal malformations Skin contact Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Potential immediate = floating in the increase in fetal deaths skeletal malformations <	Skin contact	: Causes skin irritation. May cause an allergic skin reaction.
Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing nausea or vomiting headache drowsiness/fatigue dizzinessi/ertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Jugestion : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential lelayed effects : Not available. effects Potential delayed effects : Not available. effects Potential lelayed effects : Not available. effects Potential lelayed effects : Not available. effects Potential delayed effects : Not available. effects Potential lelayed effects : Not available. e	Ingestion	: Can cause central nervous system (CNS) depression.
Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing nausea or vomiting headache drowsiness/fatigue dizzinessi/ertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Jugestion : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential lelayed effects : Not available. effects Potential delayed effects : Not available. effects Potential lelayed effects : Not available. effects Potential lelayed effects : Not available. effects Potential delayed effects : Not available. effects Potential lelayed effects : Not available. e	Symptoms related to the phys	ical. chemical and toxicological characteristics
pain or initiation watering watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects : Not available. effects : Not available. <th></th> <th></th>		
Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: increase in fetal deaths skeletal malformations Delayed and immediate effects : Adverse symptoms may include the following: increase in fetal deaths skeletal malformations Delayed and immediate effects : Adverse symptoms may include the following: increase in fetal deaths skeletal malformations Delayed and immediate effects : Not available. Potential immediate : Not available. effects : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects <th>•</th> <th>pain or irritation</th>	•	pain or irritation
respiratory tract irritation coughing nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure skeletal malformations Potential immediate : Not available. Long term exposure increase in fetal deaths Potential delayed effects : Not available. Long term exposure : Not available. Potential delayed effects : Not available. Potential delayed effects : Not ava		redness
coughing nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal maiformations skeletal maiformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal maiformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths increase in fetal deaths skeletal maiformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths increase in fetal deaths skeletal maiformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure increase in fetal deaths Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Poten	Inhalation	
naušea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation redness reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: irritation redness reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Potential immediate : Not available. Potential immediate : Not available. Potential delayed effects : Not available. Potential immediate : Not available. Potential delayed effects : Not available.		
drowsiness/fatigue dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths increase in fetal deaths skeletal malformations Delayed and immediate effects : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations : Adverse symptoms may include the following: potential immediate effects : Adverse symptoms may include the following: effects : Not available. Potential delayed effects : Not available. effects : N		
dizziness/vertigo unconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects : Not available. effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available.		
Junconsciousness reduced fetal weight increase in fetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation redness reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available.		
Skin contact : Adverse symptoms may include the following: irritation redness reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Potential immediate : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available.		•
skeletal malformations skin contact : Adverse symptoms may include the following: irritation reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Potential immediate effects : Not available. effects Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available.		-
Skin contact : Adverse symptoms may include the following: irritation redness reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Potential immediate Image: Short term exposure Potential delayed effects : Not available. effects Potential delayed effects : Not available. Long term exposure effects : Not available. Potential immediate : Not available. Potential delayed effects : Not available.		
irritation reduess reduced fetal weight increase in fetal deaths increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. : effects : Potential immediate : Not available. : effects : Potential immediate : Not available. : effects : Potential immediate : Not available. : effects : Potential delayed effects : Not available. : effects : Potential delayed effects : id theffects :	Skin contact	
Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available.	Skill contact	
Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available.		
Ingestion skeletal malformations Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and another effects from short and long term exposure Short term exposure • Potential immediate : Not available. effects • Potential delayed effects : Not available. effects • Potential immediate : Not available. effects • Potential immediate : Not available. effects • Potential delayed effects : Not available. effects • Potential clayed effects : Not available.		-
Ingestion : Adverse symptoms may include the following: reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available.		
reduced fetal weight increase in fetal deaths skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available.	Ingestion	
Skeletal malformations Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available.	0	reduced fetal weight
Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure Potential immediate : Not available. Potential delayed effects : Not available. Immediate : Not available. Long term exposure Potential immediate : Not available. . . . Potential delayed effects : Not available. . . . Potential immediate : Not available. . . . Potential delayed effects : Not available. . . . Potential delayed effects : Not available. . . . Potential delayed effects : Not available. . . . Potential chronic health effects : Not available. . . . Potential chronic health effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. 		
Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available.		skeletal manormations
Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available.	Delayed and immediate effect	and also chronic effects from short and long term exposure
effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available.	<u>Short term exposure</u>	
Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Potential chronic health effects		: Not available.
Potential immediate : Not available. effects : Potential delayed effects : Not available. Potential chronic health effects	Potential delayed effects	: Not available.
effects Potential delayed effects : Not available. Potential chronic health effects	<u>Long term exposure</u>	
Potential chronic health effects		: Not available.
	Potential delayed effects	: Not available.
Not available.	Potential chronic health effe	:ts
	Not available.	

Section 11. Toxicological information

	•
General	: May cause damage to organs through prolonged or repeated exposure. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
Carcinogenicity	: Suspected of causing cancer. Risk of cancer depends on duration and level of exposure.
Mutagenicity	: No known significant effects or critical hazards.
Teratogenicity	: Suspected of damaging the unborn child.
Developmental effects	: No known significant effects or critical hazards.
Fertility effects	: Suspected of damaging fertility.

Numerical measures of toxicity

Acute toxicity estimates

Route	ATE value
Oral	10974.53 mg/kg
Dermal	4264.23 mg/kg
Inhalation (gases)	19382.88 ppm
Inhalation (vapors)	169.82 mg/l

Section 12. Ecological information

There are no data available on the product itself. The product should not be allowed to enter drains or watercourses waterways.

Section 13. Disposal considerations

Disposal methods

: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information					
	DOT Classification	TDG Classification	Mexico Classification	IMDG	ΙΑΤΑ
UN number	UN1263	UN1263	UN1263	UN1263	UN1263
UN proper shipping name	PAINT	PAINT	PAINT	PAINT	PAINT

tinformation . . .

Transport information

Soction 14

Section 14.	•				
Transport hazard class(es)	3	3	3	3	3
Packing group	11				11
Environmental hazards	No.	No.	No.	No.	No.
Additional inform	nation				
DOT Classificat	sh	ipped in quantities		uct reportable quantit	.29 L]. Package sizes ty are not subject to the RQ
TDG Classificat			s per the following s 2.18-2.19 (Class 3)		portation of Dangerous
Special precautio	up		Ensure that persons		eed containers that are oduct know what to do in the
Transport in bulk to IMO instrumen	-	ot available.			

The actual shipping description for this product may vary based several factors including, but not limited to, the volume of material, size of the container, mode of transport and use of exemptions or exceptions found in the applicable regulations. The information provided in Section 14 is one possible shipping description for this product. Consult your shipping specialist or supplier for appropriate assignment information.

Section 15. Regulatory information

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) SARA 304 RQ	: Listed
SARA 304 RQ	: 210728459.8 lbs / 95670720.8 kg [26716205.7 gal / 101131840.1 L]
SARA 311/312	
Classification	: FLAMMABLE LIQUIDS - Category 2 ACUTE TOXICITY (inhalation) - Category 4 SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2 SKIN SENSITIZATION - Category 1 CARCINOGENICITY - Category 2 TOXIC TO REPRODUCTION - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Narcotic effects) - Category 3
	SPEČIFÍC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 2

<u>SARA 313</u>

Section 15. Regulatory information

	Product name	CAS number	%
Form R - Reporting requirements	XYLENE TOLUENE ETHYLBENZENE NAPHTHALENE	1330-20-7 108-88-3 100-41-4 91-20-3	≥10 - ≤25 ≤10 ≤10 ≤0.3
Supplier notification	XYLENE TOLUENE ETHYLBENZENE NAPHTHALENE	1330-20-7 108-88-3 100-41-4 91-20-3	≥10 - ≤25 ≤10 ≤10 ≤0.3

SARA 313 notifications must not be detached from the SDS and any copying and redistribution of the SDS shall include copying and redistribution of the notice attached to copies of the SDS subsequently redistributed.

Inventory list

- Canada
- : At least one component is not listed in DSL but all such components are listed in NDSL.
- United States :
 - : All components are listed or exempted.

Section 16. Other information

Hazardous Material Information System (U.S.A.)



Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

National Fire Protection Association (U.S.A.)



Reprinted with permission from NFPA 704-2001, Identification of the Hazards of Materials for Emergency Response Copyright ©1997, National Fire Protection Association, Quincy, MA 02269. This reprinted material is not the complete and official position of the National Fire Protection Association, on the referenced subject which is represented only by the standard in its entirety.

Copyright ©2001, National Fire Protection Association, Quincy, MA 02269. This warning system is intended to be interpreted and applied only by properly trained individuals to identify fire, health and reactivity hazards of chemicals. The user is referred to certain limited number of chemicals with recommended classifications in NFPA 49 and NFPA 325, which would be used as a guideline only. Whether the chemicals are classified by NFPA or not, anyone using the 704 systems to classify chemicals does so at their own risk.

<u>History</u>

Date of issue	: 1/18/2024
Version	: 15.01
	Product stewardship and regulatory compliance.

Section 16. Other information

Key to abbreviations	: ATE = Acute Toxicity Estimate
	GHS = Globally Harmonized System of Classification and Labelling of Chemicals
	IATA = International Air Transport Association
	IBC = Intermediate Bulk Container
	IMDG = International Maritime Dangerous Goods
	LogPow = logarithm of the octanol/water partition coefficient
	MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
	UN = United Nations

Indicates information that has changed from previously issued version.

Notice to reader

This product is intended for industrial use only.

Safety Data Sheet (SDS) content is believed to be accurate as of its issue date, but is subject to change as new information is received by Axalta Coatings Systems, LLC or any of its subsidiaries or affiliates (Axalta). This SDS may incorporate information that has been provided to Axalta by its suppliers. Users should ensure that they are referring to the most current version of the SDS. Users are responsible for following the precautions identified in this SDS. It is the users' responsibility to comply with all laws and regulations applicable to the safe handling, use, and disposal of the product.

Users of Axalta products should read all relevant product information prior to use, and make their own determination as to the suitability of the products for their intended use. Except as otherwise required by applicable law, AXALTA MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. The information on this SDS relates only to the specific product identified in Section 1, Identification, and does not relate to its possible use in combination with any other material or in any specific process. If this product is to be used in combination with other products, Axalta encourages you to read and understand the SDS for all products prior to use.

© 2022 Axalta Coating Systems, LLC and all affiliates. All rights reserved. Copies may be made only for those using Axalta Coating Systems products.